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ABSTRACT
Immunomodulatory drugs (IMiDs) have potent anti-tumor activities in Multiple 
Myeloma (MM) and are able to enhance the cytotoxic function of Natural Killer 
(NK) cells, important effectors of the immune response against MM. Here, we show 
that these drugs can enhance the expression of the NKG2D and DNAM-1 activating 
receptor ligands MICA and PVR/CD155 in human MM cell lines and primary malignant 
plasma cells. Depletion of cereblon (CRBN) by shRNA interference strongly impaired 
upregulation of these ligands and, more interestingly, IMiDs/CRBN-mediated 
downregulation of the transcription factors Ikaros (IKZF1), Aiolos (IKZF3) and IRF4 
was critical for these regulatory mechanisms. Indeed, shRNA knockdown of IKZF1 
or IKZF3 expression was both necessary and sufficient for the upregulation of MICA 
and PVR/CD155 expression, suggesting that these transcription factors can repress 
these genes; accordingly, the direct interaction and the negative role of IKZF1 and 
IKZF3 proteins on MICA and PVR/CD155 promoters were demonstrated. Finally, MICA 
expression was enhanced in IRF4-silenced cells, indicating a specific suppressive role 
of this transcription factor on MICA gene expression in MM cells. 
Taken together, these findings describe novel molecular pathways involved in 
the regulation of MICA and PVR/CD155 gene expression and identify the transcription 
factors IKZF-1/IKZF-3 and IRF4 as repressors of these genes in MM cells.
INTRODUCTION
Multiple Myeloma (MM) is an incurable 
hematologic cancer characterized by clonal expansion of 
cancerous plasma cells in the bone marrow [1, 2] and its 
development is supported by a progressive impairment 
of immunosurveillance, mainly attributable to T and NK 
cell alterations [3-5]. NK cells significantly contribute 
to anti-tumor immune response, due to their ability to 
recognize and lyse cancer cells. The NK cell cytotoxic 
activity is controlled by integrated signals delivered from 
a complex set of inhibitory and activating receptors [6, 7]. 
In this regard, NKG2D and DNAM-1 are two activating 
receptors shown to play a prominent role in tumor 
immunosurveillance. 
NKG2D interacts with multiple ligands, including 
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MHC class I-related chain A/B (MICA/B) and UL16 
binding proteins (ULBPs), while DNAM-1 recognizes two 
nectin-like proteins, the poliovirus receptor (PVR/CD155) 
and Nectin-2 (Nec-2). 
NKG2D ligands (NKG2DLs) show a restricted 
expression on healthy cells, however they are frequently 
overexpressed in a wide range of pathological conditions, 
including cancer and infection. In tumor cells, their 
expression is controlled at different levels by complex 
mechanisms only partially characterized. In particular, 
oncogenic proliferative and stress signaling pathways 
linked to the tumorigenic process, such as DNA damage 
response (DDR), can increase their basal expression 
[8-10]. Moreover, to escape immune cell mediated 
recognition, tumors can downregulate NKG2DLs 
expression, via proteolytic shedding from the cell surface 
and/or excretion in exosomes [11, 12]. 
DNAM-1 ligands (DNAM1Ls) are ubiquitously 
expressed in various tissues, and their levels increase 
in different tumor cells, but the mechanisms leading to 
their regulation are largely unknown [13]. In this regard, 
evidence is accumulating that the engagement of NKG2D 
and DNAM-1 activating receptors is critical for NK-
mediated killing of myeloma cells, which express NKG2D 
and DNAM-1 ligands [4, 14-18]. Thus, improving NK 
cell responsiveness may be a promising therapeutic 
approach to treat MM; in particular, the modulation of the 
balance between activating and inhibitory NK cell signals 
and sensitization of cancer cells to NK cell mediated-
cytotoxicity may significantly contribute to enhance anti-
myeloma immune response. 
Of note, among novel therapeutic agents used 
in MM clinical management, IMiDs [thalidomide, 
lenalidomide (CC-5013) and pomalidomide (CC4047)], 
have the ability to modulate humoral as well as cellular 
components of the innate and adaptive immune responses, 
including NK cell activity against cancer cells [5, 19-22]. 
In particular, an increased number of NK cells expressing 
higher levels of the activating receptors NKG2D, NKp30 
and NKp44 has been observed in MM patients during 
IMiDs therapy [23, 24]; moreover, IMiDs enhance NK cell 
antibody-dependent cell-mediated cytotoxicity (ADCC) 
activity toward MM cells [25], and can sensitize myeloma 
cells to NK cell cytotoxicity by inhibiting the expression 
of PD-L1 [26]. 
In the last few years, the mechanism of action of 
IMiDs has becoming increasingly clear. The cellular target 
of these drugs is cereblon (CRBN), a ubiquitous protein 
which functions as a substrate receptor for the Cullin-
4-RING Ubiquitin Ligase (CLR4) complex, containing 
Cullin-4 (CUL4), DNA damage binding protein-1 (DDB1) 
and the RING-finger protein (ROC1) [29, 30]. 
CRBN is essential for the anti-myeloma activity 
of IMiDs and loss of this protein causes drug resistance 
in MM cells [30, 31]. IMiDs binding to CRBN alters the 
function of the CLR4 [29]; in particular enforced binding 
of IMiDs to CRBN is able to disrupt the recruitment 
of some substrates and, at the same time, promotes the 
ubiquitination of other proteins, suggesting the possibility 
that a neomorphic structure is involved [32, 33]. 
In this context, recent papers described the capability 
of IMiDs to induce CRBN-dependent degradation of the 
Ikaros family zinc finger protein-1 (IKZF1, Ikaros) and 
3 (IKZF3, Aiolos) [34, 35], two transcription factors 
involved in lymphoid development and differentiation 
and highly expressed in B cell malignancies, including 
MM [36, 37]. Loss of these proteins was shown to 
mediate important therapeutic activities of IMiDs, such 
as increased IL-2 production by T cells [35, 38] or anti-
proliferative effects in MM cells [34, 35]. Interestingly, in 
MM cells IKZF1 and IKZF3 have also emerged as positive 
regulators of the expression of the IRF4 gene [34-36], a 
haemopoietic cell-restricted transcription factor, identified 
as a key regulator of malignancy-specific gene expression 
in MM [39, 40]. In this regard, IMiDs were found to 
inhibit IRF4 expression at transcriptional level, mainly 
via downregulation of IKZF1/3 transcription factors [34].
In this study, we define novel regulatory 
mechanisms of NK cell-activating ligand gene 
expression in MM cells. We demonstrate that IMiDs can 
upregulate MICA and PVR/CD155 surface expression, 
enhancing NK cell recognition and killing. A prominent 
role in these regulatory mechanisms is played by the 
transcription factors IKZF1/3 and IRF4, able to repress 
the basal transcription of mica and pvr gene expression. 
Lenalidomide-induced downregulation of these 
transcription factors leads to de-repression of mica and 
pvr promoter activity, and consequently to increased gene 
transcription. 
Thus, we identified IKZF1/3 and IRF4 as 
“druggable” transcriptional repressors of NK cell-
activating ligand expression in MM cells. 
RESULTS
IMiDs upregulate MICA and PVR/CD155 
expression on human Multiple Myeloma cells and 
enhance their recognition by NK cells
In the last few years, our laboratory has investigated 
the expression and regulation of different NKG2D and 
DNAM-1 ligands on human MM cells in response to 
anti-myeloma agents [16, 27, 41]. In this context, we 
and other authors have initially reported the capability 
of lenalidomide to increase the expression of several NK 
cell-activating ligands on MM cells [27, 28]; however, 
the molecular mechanisms involved have not been 
investigated yet. To better analyse the effects of IMiDs on 
the expression of NK cell-activating ligands, we initially 
performed flow cytometric analyses on SKO-007(J3) cells, 
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Figure 1: IMiDs upregulate MICA and PVR/CD155 expression on human Multiple Myeloma cells and enhance their 
recognition by NK cells. A. MICA, MICB and PVR/CD155 surface expression were analyzed by flow cytometry on SKO-007(J3) 
cells treated with lenalidomide (Lena) (10 µM) for 72h. The grey colored histograms represent basal expression of the indicated ligand, 
while thick black histograms represent the expression after treatment with the drug. Data are representative of one out of four independent 
experiments. B. The MFI of MICA, MICB and PVR/CD155 were calculated based on at least four independent experiments and evaluated 
by paired Student t test (*P< 0.05). Histograms represent the MFI of specific mAb - MFI of isotype control. C. NK cells, prepared from 
PBMCs of healthy donors, were incubated with SKO-007(J3) cells, untreated or treated with lenalidomide (Lena) for 72h, and used as 
target cells in a degranulation assay. The assay was performed at the effector:target (E:T) ratio of 2.5:1. After 3 hours at 37°C, cells were 
stained with anti-CD56, anti-CD3 and anti-CD107a mAbs. Cell surface expression of CD107a was analyzed on FSC/SSC-gated and 
CD56+CD3- cells. In order to evaluate the role of NKG2D and DNAM-1, the assay was performed in parallel treating NK cells with 
blocking anti-DNAM-1 or anti-NKG2D antibodies. The MFI of CD107a were calculated based on at least three independent experiments 
and evaluated by paired Student t test (*P< 0.05). For each treatment, histograms represent the MFI of specific mAb - MFI of isotype 
control. D. CD138- bone marrow cells, cultured for 2 days in complete medium supplemented with IL-2 (200 U/mL), were incubated with 
purified autologous myeloma cells, untreated or treated with lenalidomide (Lena) for 48h, and used as target cells in a degranulation assay. 
The assay was performed at the effector:target (E:T) ratio of 2.5:1. After 3 hours at 37°C, cells were stained with anti-CD56, anti-CD3 and 
anti-CD107a mAbs. Cell surface expression of CD107a was analyzed on CD56+CD3- cells. Results obtained from two patients (P11 and 
P12) are represented.
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a MM cell line known to basally express MICA/B and 
PVR/CD155 [16], after 72h-treatment with micromolar 
concentrations of lenalidomide or pomalidomide. We 
observed that these drugs upregulate the basal expression 
of MICA and PVR/CD155 on SKO-007(J3) cells, with no 
significant effects on MICB levels (Fig. 1A and 1B and 
Suppl. Fig. 1A and 1B). Similar data were also obtained 
in other MM cell lines that constitutively express either 
one of these ligands: ARP-1 and JJN3 cells for MICA and 
KMS27 and OPM-2 cells for PVR/CD155 (Suppl. Fig. 2). 
Moreover, where not expressed, we did not observe a neo-
induction of these ligands in IMiDs-treated cells (data not 
shown).
We could confirm these results also in CD138+ MM 
cells from the bone marrow of MM patients, showing 
higher surface levels of MICA and/or PVR/CD155 
following treatment with lenalidomide (Table 1 and 2). 
Of note, in some patient-derived PCs, the drug did not 
show a significant effect on either MICA or PVR/CD155, 
independently from the clinical stage of disease and from 
basal level expression of these ligands, suggesting that 
different gene-specific mechanisms of regulation could be 
involved.
As regards the other NKG2D and DNAM-1 ligands, 
SKO-007(J3) cells express low or undetectable levels of 
ULBP2/5/6 or ULBP1, ULBP3 and Nec-2 respectively, 
and lenalidomide did not modify their surface levels 
(Suppl. Fig. 3). These treatments did not affect the cell 
viability of these cell lines after 72h-treatment, as assessed 
by PI staining (data not shown).
To evaluate the functional consequence of IMiDs-
induced changes of MICA and PVR/CD155 expression, 
we analyzed the lysosomal marker CD107a (a surrogate 
marker for granule mobilization [42]) on NK cells isolated 
from healthy donors against SKO-007(J3) cells, untreated 
or treated with lenalidomide as described above, by FACS 
analysis. As shown in Fig. 1C, basal expression of CD107a 
on NK cells was enhanced when co-cultured with SKO-
Table 1: Clinical parameters of MM patients. Patients were classified according to Durie and Salmon’s Staging System.
Patient no. Sex/Age Clinical Stage Monoclonal Ig % PCs in BM
1 M/67 Relapse IgG-k 37
2 F/78 Relapse IgG-k 11
3 M/58 Relapse IgG-k 49
4 F/73 Smoldering IgG-k 38
5 F/79 Onset IgG-k 65
6 M/79 Smoldering IgG-L 32
7 F/73 Relapse IgG-k 19
8 F/58 Relapse IgG-k 28
9 M/61 Relapse Micro-k 60
10 F/73 Smoldering IgA-L 34
11 F/74 Onset IgG-k 22
12 M/74 Onset IgG-k 22
13 F/74 Onset IgG-L 72
14 F/61 Relapse IgG-k 39
15 M/79 Relapse IgG-k 43
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007(J3) target cells exposed to lenalidomide; this effect 
was significantly inhibited by the combined blocking 
anti-NKG2D plus anti-DNAM-1 mAbs, indicating that 
stimulation of NK cell degranulation was dependent on 
both NKG2D and DNAM-1 activation. Accordingly, a 
higher capability of degranulation was also observed in 
patient-derived NK cells against lenalidomide-treated 
autologous MM targets (Fig. 1D).
Altogether, these data show that IMiDs treatment 
of human MM cells enhances MICA and PVR/CD155 
membrane expression by increasing their susceptibility to 
NK cell recognition and killing.
MICA and PVR/CD155 upregulation by IMiDs 
involves transcriptional mechanisms
To examine whether the upregulation of MICA and 
PVR/CD155 membrane expression by IMiDs could be 
associated with increased mRNA levels, total RNA was 
isolated from SKO-007(J3) cells exposed to lenalidomide 
or pomalidomide and analyzed by Real-Time qRT-PCR. 
As shown in Fig. 2A (and Suppl. Fig. 4), we found a 
significant increase of MICA and PVR/CD155 mRNA 
levels in treated cells, whereas, in accordance with the 
results at protein level, we did not detect any changes of 
MICB transcripts. Moreover, similar results were obtained 
in lenalidomide-treated MM cells isolated from three 
different patients (Fig. 2B).
To explore the possibility that these drugs 
could increase MICA and PVR/CD155 expression at 
Table 2: Upregulation of MICA and PVR/CD155 expression on patient-derived PCs cells upon treatment with 
lenalidomide. 
Patient  MICA  MICB PVR/CD155
Unstim. Lena Unstim. Lena Unstim. Lena
     1 1.7 1.7 1.5 1.5 4.9 13.9
     2 2.4 1 2.1 2.4 1 6
     3 2.4 4.9 2.5 1 2.3 13.9
     4 5.9 8.1 1.3 1.2 1.3 1.3
     5 1.7 4.6 1 1.7 3.7 3
     6 1.6 1 1 1.2 1 14.4
     7 1 1 1,4 1.4 5.5 73.6
     8 13 19.3 1.7 2 1.2 1
     9 1 2.6 1 1.4 2.2 1.7
    10 2.3 3.8 1 1.6 1.3 4.3
MICA, MICB and PVR/CD155 surface expression was analyzed by flow cytometry on patient MM cells treated with 
lenalidomide (Lena) for 48h. For each treatment, value ratio between MFI of specific mAb and MFI of isotype control 
was reported.
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Figure  2: Lenalidomide increases MICA and PVR/CD155 mRNA expression and promoter activation in SKO-007(J3) 
cells. A. Real Time PCR analysis of total mRNA obtained from SKO-007(J3) cells, untreated or treated with lenalidomide (Lena) as 
described above for 24h and 48h. Data, expressed as fold change units, were normalized with GAPDH and referred to the untreated cells, 
considered as calibrator and represent the mean of 3 experiments (*P< 0.05). B. Real Time PCR analysis of total mRNA obtained from 
purified CD138+ cells untreated or treated with lenalidomide (Lena) for 24h in complete medium supplemented with 20 ng/ml IL-3 and 2 
ng/ml IL-6. Data, expressed as fold change units, were normalized with GAPDH and referred to the untreated cells considered as calibrator. 
C. SKO-007(J3) cells were infected with lentivirus encoding LV control, LV-MICA or LV-PVR/CD155 promoter, obtained as described 
in Materials and Methods. After 48h treatment with lenalidomide (Lena), cellular medium were harvested and analyzed for the Gaussia 
Luciferase and SEAP assays. Results are expressed as relative luciferase activity normalized to SEAP activity and represent the mean value 
from four independent experiments (*P< 0.05).
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transcriptional level, we analyzed their effect on SKO-
007(J3) cells stably infected with a lentivirus carrying 
a MICA or a PVR/CD155 5’-flank (promoter fragment) 
upstream of a GLuc reporter gene. As shown in Fig. 
2C, lenalidomide enhanced the activity of the reporter 
gene driven by a 1.2 kb fragment of the mica or a 1.3 kb 
fragment of the pvr gene promoter. 
Thus, MICA and PVR/CD155 mRNA expression 
and promoter activity are enhanced by IMiDs in MM cells.
IMiDs-induced MICA and PVR/CD155 
upregulation is CRBN-dependent and involves 
IKZF1/3 transcription factors 
To investigate the role of CRBN in MICA and 
PVR/CD155 upregulation by IMiDs, we first treated 
SKO-007(J3) cells with phthalimide, a thalidomide 
analogue lacking the glutarimide moiety, the structural 
component mediating binding to CRBN [32]. We did 
not observe any changes in ligand expression on cells 
exposed to phthalimide for 72h, also using doses two 
times higher than those of lenalidomide, thus suggesting 
the involvement of CRBN in these mechanisms (Suppl. 
Fig. 5). Then, we tested whether the absence of CRBN 
could modify IMiDs effects on ligand expression. To this 
aim, we used a lentiviral vector expressing CRBN shRNA 
to generate SKO-007(J3) cells with reduced expression of 
this protein. Since stable CRBN depletion is cytotoxic for 
myeloma cells [31], these experiments were performed 
using transient infections. As shown in Fig. 3A-3C, 
lenalidomide failed to augment MICA and PVR/CD155 
levels in cells with reduced levels of CRBN. 
In order to identify possible molecular mediators 
involved in the upregulation of MICA and PVR/CD155 
by IMiDs, we focused our attention on the role of the 
transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), 
recently identified as IMiDs-bound CRBN downstream 
targets in MM cells [34-36]. 
We first confirmed the capability of lenalidomide and 
pomalidomide to promote IKZF1 and IKZF3 degradation 
in our experimental system (Suppl. Fig. 6A-6D); then, 
we examined whether the absence of these proteins could 
affect MICA and PVR/CD155 basal expression. To this 
purpose, we infected SKO-007(J3) cells with lentiviral 
vectors expressing IKZF1 or IKZF3 shRNAs along with 
green fluorescent protein (GFP) (Suppl. Fig. 7A and 7B). 
As shown in Fig. 3D-3G, by comparing ligand expression 
of shRNA-transduced (GFP+) and shRNA-non-transduced 
(GFP-) cells (Suppl. Fig. 7C), we could appreciate how 
knockdown of IKZF1 or IKZF3 proteins was sufficient 
to augment MICA and PVR/CD155 surface levels, 
suggesting a repressive role of these transcription factors 
on basal expression of these ligands in MM cells, whereas 
the expression of MICB was not affected. 
To better evaluate and confirm these results, we 
infected SKO-007(J3) cells with a retrovirus expressing 
IK6-DN along with GFP, an isoform of Ikaros lacking 
the DNA binding domain and able to negatively interfere 
with the activity of wild-type Ikaros family members [43, 
44]. Flow cytometric analysis on these cells revealed a 
significant increase of basal membrane expression of 
MICA and PVR/CD155 as compared to cells infected 
with an empty control vector (Suppl. Fig. 8A-8C). To 
determine the effects of IK6-DN on the expression of 
MICA and PVR/CD155 transcripts, GFP+ infected cells 
were isolated by cell sorting, for RNA extraction and Real-
Time qRT-PCR analysis. Consistent with FACS analysis, 
overexpression of IK6-DN was able to increase MICA 
and PVR/CD155 basal mRNA levels (Suppl. Fig. 8D); 
moreover, as observed in IKZF1 or IKZF3 silenced cells, 
both MICB surface levels and transcripts were unaltered 
by ectopic expression of IK6-DN. Accordingly, we also 
observed significantly lower MICA and PVR/CD155 
surface levels in wt-IKZF1-transduced 293T cells, that 
express IKZF1 at very low levels (Suppl. Fig. 8E, 8F). 
To examine possible inhibitory effects of these 
transcription factors on mica and pvr promoter activity, 
we performed transient transfection assays in 293T cells. 
Regarding mica, a search for sequence homology revealed 
two proximal putative Ikaros response elements in a region 
spanning the first -270 bp of its promoter (Table 3). We 
observed a significant repressive effect mediated by IKZF1 
overexpression on the luciferase activity driven by a -270 
bp 5’-flank of mica promoter. However, the inhibitory 
effect of IKZF1 was significantly reduced on two mutated 
versions of the -270 bp mica promoter (indicated as 270bp 
MICA-DEL1 and 270bp MICA-DEL2), in which either 
one putative Ikaros site was removed by site-directed 
mutagenesis (Fig. 4A), thus indicating that binding of this 
transcription factor to both sites is required for repression. 
Regarding pvr, we used progressive deletions of 
this promoter and delineated a fragment, spanning from 
-470 bp to -343 bp (deletion PVR-A/PVR-B), responsive 
to the inhibitory activity of this transcription factor and 
containing a putative Ikaros consensus site (Fig. 4C).
Accordingly, we demonstrated the capability of 
IKZF1 and IKZF3 proteins to directly bind to mica and 
pvr promoters, in the regions encompassing these Ikaros 
consensus sites by ChIP assays (Fig. 4B and 4D).
Finally, we did not observe any increase of ligand 
expression in lenalidomide-treated SKO-007(J3) cells 
overexpressing IKZF1-Q146H, a mutant form of Ikaros 
incapable of binding CRBN and resistant to IMiDs-
mediated degradation [34] (Fig. 5A-5C), thus confirming 
the repressive effect of IKZF1/3 on MICA and PVR/
CD155 expression, and indicating that IMiDs can blunt 
this effect.
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Figure  3: MICA and PVR/CD155 upregulation by IMiDs is CRBN-dependent and involves IKZF1/3 transcription 
factors. A. Total mRNA was obtained from SKO-007(J3) cells transiently infected with lentivirus pLKO-shRNA-CRBN or pLKO non-
targeting shRNA (control) (72h) and analyzed for CRBN mRNA expression by Real-Time qRT-PCR. Data were normalized with GAPDH 
and referred to the cells infected with non-target shRNA, considered as calibrator. B. MICA, MICB and PVR/CD155 surface expression 
were analyzed by flow cytometry on SKO-007(J3) pLKO non-target shRNA or pLKO-shRNA-CRBN cells, treated with lenalidomide 
(Lena) as described above. The grey colored histograms represent basal expression of the indicated ligand, while thick black histograms 
represent the expression after treatment with the drug. Data are representative of one out of five independent experiments. C. The MFI 
of MICA, MICB and PVR/CD155 were calculated based on at least five independent experiments and evaluated by paired Student t test 
(*P< 0.05). For each treatment, histograms represent the MFI of specific mAb - MFI of isotype control. D., F. MICA, MICB and PVR/
CD155 surface expression were analyzed by flow cytometry on pLKO-IKZF1/GFP or F., G.) pLKO-IKZF3/GFP -lentivirus transiently 
infected SKO-007(J3) cells (72h), by gating on GFP+ and GFP- cells as indicated in Suppl. Fig. 7C. Data are representative of one out of 
four independent experiments. The grey colored histograms represent the expression of the indicated ligand in GFP- cells while thick black 
histograms represent the expression of the indicated ligand in GFP+ infected cells. E., G. The MFI of MICA, MICB and PVR/CD155 were 
calculated based on at least four independent experiments and evaluated by paired Student t test (*P< 0.05). For each treatment, histograms 
represent the MFI of specific mAb - MFI of isotype control.
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Figure 4: IKZF1/3 transcription factors repress mica and pvr promoter activity. A., C. 293T cells were transiently co-
transfected with the indicated -270bp-mica reporter vectors or different pvr promoter deletions and an IKZF1 expression vector as described 
in Materials and Methods. After 48h, cells were harvested and protein extracts were prepared for the luciferase assay. Data were normalized 
to protein concentration and β-galactosidase activity and represent the mean of three independent experiments (*P< 0.05). B., D. In vivo 
binding of IKZF1 and IKZF3 to the MICA and PVR promoters was examined in ChIP analysis. Samples were immunoprecipitated from 
sonicated lysates of SKO-007(J3) cells using an antibody against human IKZF1 or IKZF3 proteins or isotype control. After reversing 
the cross-linking, DNA was precipitated and Real-Time PCR was performed using primers to amplify the mica or pvr promoter region 
encompassing the Ikaros responsive element (IK-RE) (indicated in the figures). Results are expressed as Relative Enrichment as compared 
to the input. Data represent the mean of n=3 experiments (*P< 0.05). IK-RE: Ikaros Responsive Element.
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Figure 5: A mutant form of Ikaros incapable of binding CRBN abrogates MICA and PVR/CD155 upregulation 
by IMiDs. A. Western Blot analysis of total cellular proteins from SKO-007(J3) cells infected with a control empty Lenti-Ires-GFP 
vector or Lenti-Ires-GFP-IKZF1-V1-Q146H, left unstimulated or stimulated with lenalidomide (Lena) for 72h. The proteins transferred 
to nitrocellulose membranes were stained with Ponceau to verify that similar amounts of proteins had been loaded in each lane and 
immunoblotted for IKZF1 and Actin. B. MICA, MICB and PVR/CD155 surface expression were analyzed by flow cytometry on SKO-
007(J3) cells transiently infected with lentiviral vectors encoding GFP or GFP and IKZF1-V1-Q146H, untreated or treated with lenalidomide 
(Lena) as described above. Data are representative of one out of five independent experiments. The grey colored histograms represent basal 
expression of the indicated ligand, while thick black histograms represent the expression after treatment with lenalidomide (Lena). C. The 
MFI of MICA, MICB and PVR/CD155 were calculated based on at least five independent experiments and evaluated by paired Student t 
test (*P< 0.05). For each treatment, histograms represent the MFI of specific mAb - MFI of isotype control.
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Figure 6: IRF4 represses MICA expression. A. Lysates of SKO-007(J3) cells untreated or treated with lenalidomide (Lena) for 24h, 
48h and 72h were subjected to Western Blotting using anti-IRF4 and Actin antibodies. The proteins transferred to nitrocellulose membranes 
were stained with Ponceau to verify that similar amounts of proteins had been loaded in each lane. Data are representative of one out of 
three independent experiments. B. Immunoblotting analysis for IRF4 and Actin of total cellular proteins from SKO-007(J3) cells infected 
with two different lentiviruses, pLKO expressing IRF4-shRNA or pLKO non-targeting shRNA (control) for 72h. The proteins transferred 
to nitrocellulose membranes were stained with Ponceau to verify that similar amounts of proteins had been loaded in each lane. Data are 
representative of one out of three independent experiments. C. MICA, MICB and PVR/CD155 surface expression were analyzed by flow 
cytometry on pLKO-control (non-targeting) or pLKO-IRF4-lentivirus infected SKO-007(J3) cells (72h). Data are representative of one 
out of four independent experiments. The grey colored histograms represent the expression of the indicated ligand in cells transduced 
with the pLKO-control, while thick black histograms represent the expression in cells infected with pLKO-IRF4. D. Total RNA were 
also isolated from infected cells for Real-Time qRT-PCR analysis. Data, expressed as fold change units, were normalized with GAPDH 
and referred to the cells infected with non-target shRNA, considered as calibrator and represent the mean of 3 experiments (*P< 0.05). E. 
NK cells prepared from PBMCs of healthy donors were incubated with SKO-007(J3) cells after 72h-infection with pLKO-control (non-
targeting) or pLKO-IRF4 shRNA and used as target cells in a degranulation assay. The assay was performed as described above. Results 
are representative of one out of three independent experiments.
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Figure 7: MICA inhibition by IRF4 depends on its DNA binding activity. A. MICA and PVR/CD155 surface expression were 
analyzed by flow cytometry on SKO-007(J3) cells transduced with a retrovirus expressing IRF4 (1-405) or IRF4 (403-1356) and GFP, after 
72h treatment with lenalidomide (Lena). Data are representative of one out of three independent experiments. The grey colored histograms 
represent basal expression of the indicated ligand, while thick black histograms represent the expression after treatment with the drug in 
GFP positive cells. B. The MFI of MICA, MICB and PVR/CD155 were calculated based on at least four independent experiments and 
evaluated by paired Student t test (*P< 0.05). For each treatment, histograms represent the MFI of specific mAb - MFI of isotype control.
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The transcription factor IRF4 inhibits MICA 
expression in MM cells
An additional target of IMiDs in MM cells is IRF4, 
a transcription factor positively regulated by IKZF1/3 and 
inhibited by IMiDs/CRBN-mediated degradation of these 
proteins [34-36]. 
We investigated its possible involvement in ligand 
upregulation, as no evidence is available about a role of 
this transcription factor in the regulation of MICA and 
PVR/CD155 gene expression. 
Consistent with other studies [34-36, 45], western 
blot analysis confirmed a significant IRF4 downregulation 
in SKO-007(J3) cells exposed to lenalidomide or 
pomalidomide (24 to 72h) (Fig. 6A and Suppl. Fig. 9). 
Therefore, we assessed the possible impact of direct 
IRF4 depletion by shRNA interference (Fig. 6B) on 
MICA and PVR/CD155 ligand expression. Since stable 
IRF4 depletion is cytotoxic for myeloma cells [40], these 
experiments were performed using transient infections.
Compared with non-targeting shRNA-infected 
cells, IRF4 shRNA-transduced cells expressed higher 
MICA surface levels, whereas MICB and PVR/CD155 
membrane expression were unaffected (Fig. 6C). 
Accordingly, Real-Time qRT-PCR analysis showed that 
IRF4 silencing enhances only MICA mRNA expression 
(Fig. 6D). Moreover, we observed that the increased 
MICA membrane expression in IRF4 shRNA-transduced 
cells could enhance their capability to stimulate NK cell 
degranulation in an NKG2D-dependent manner (Fig. 6E).
These data indicate that in MM cells, IRF4 can 
repress MICA expression both at protein and mRNA 
levels.
To gain insight into the molecular mechanism(s) 
that mediate the repressive activity of IRF4 on MICA 
expression, we performed a structure/function analysis 
of IRF4 by infecting SKO-007(J3) cells with retrovirus 
expressing mutant forms of IRF4 and GFP. As shown in 
Fig. 7A and B, ectopic expression of a truncated form of 
IRF4 consisting of its N-terminal DNA binding domain 
(IRF4 1-405) (GFP+ cells) was sufficient to specifically 
increase MICA expression, presumably by competing with 
and inhibiting the endogenous wild-type IRF4 function. 
On the contrary, overexpression of the C-terminal 
association domain of IRF4 (IRF4 403-1356) did not 
affect either basal or lenalidomide-induced levels of this 
ligand, suggesting that DNA binding activity of IRF4 is 
necessary but not sufficient for MICA repression.
These observations indicate that IMiDs may involve 
both IKZF1/3 proteins depletion and IRF4 downregulation 
into increased MICA expression. 
Interestingly, by analyzing the induction of ligands 
at early times, treatment with lenalidomide was able to 
increase MICA and PVR/CD155 mRNA levels as early 
as 3 to 18 h (Fig. 8A and 8B), inducing IKZF1 and 
IKZF3 degradation with no significant effect on IRF4 
levels (Fig. 8C), thus suggesting that IKZF1/3 and IRF4 
could contribute to MICA upregulation through a time-
sequential modulation of their expression.
Finally, knockdown of IRF4 did not modify either 
Table 3: Schematic representation of putative IKAROS response elements of mica and pvr promoter.
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Figure 8: Loss of the transcription factors IKZF1/3 and IRF4 contributes to IMiDs-mediated MICA upregulation 
with different kinetics. A., B. Real Time PCR analysis of total mRNA obtained from SKO-007(J3) cells, unstimulated or treated 
with lenalidomide (Lena) for the indicated times. Data, expressed as fold change units, were normalized with GAPDH and referred to 
the untreated cells considered as calibrator and represent the mean of 3 experiments (*P< 0.05). C. SKO-007(J3) cells were treated 
with lenalidomide (Lena) for the indicated times and cell lysates were immunoblotted for IRF4, IKZF1, IKZF3 and Actin. The proteins 
transferred to nitrocellulose membranes were stained with Ponceau to verify that similar amounts of proteins had been loaded in each lane. 
Data are representative of one out of three independent experiments. D. Immunoblotting analysis for IRF4, Blimp-1, IKZF1, IKZF3 and 
Actin of total cellular proteins from SKO-007(J3) cells infected with a lentivirus expressing IRF4 shRNA or pLKO-control (non-targeting) 
shRNA. The proteins transferred to nitrocellulose membranes were stained with Ponceau to verify that similar amounts of proteins had been 
loaded in each lane. Data are representative of one out of three independent experiments.
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IKZF1 or IKZF3 expression, while it could abolish the 
expression of Blimp-1 (a known target used here as a 
control) [46] (Fig. 8D), thus excluding the possibility that 
the IRF4-mediated negative regulation of MICA might 
indirectly depend on IKZF1/3 transcription factors [47]. 
Altogether, these observations identify the 
transcription factor IRF4 as a novel negative regulator of 
MICA gene expression in MM cells and provide evidence 
that its downregulation contributes to MICA upregulation 
by IMiDs. 
DISCUSSION
IMiDs are highly effective drugs for the treatment 
of MM and different biological activities are responsible 
for their anti-myeloma properties [21, 22, 48, 49]. In 
particular, a number of evidences in myeloma patients 
describe the anti-tumor potential of NK cells in response 
to IMiDs [19, 20, 23, 24], as well as the sensitization of 
myeloma cells to NK cell-mediated lysis [27, 28]. 
In this study, we investigated the effects of IMiDs 
on NK cell-activating ligand expression in MM cells. We 
found a significant upregulation of MICA and PVR/CD155 
mRNA and cell surface expression by lenalidomide and 
pomalidomide; accordingly, NK-cell degranulation was 
enhanced upon interaction with IMiDs-treated tumor cells. 
IMiDs bind to CRBN, a component of the ubiquitin 
ligase complex CLR4; the drug-CRBN interaction alters 
its specificity to induce ubiquitylation and degradation of 
several proteins, involved in the regulation of different 
molecular pathways [34-36]. In this regard, the amount 
of three different transcription factors, IKZF1, IKZF3 
and IRF4 was widely described to decrease in MM cells 
exposed to IMiDs.
 Our findings demonstrate that IMiDs-CRBN-
IKZF1/3-IRF4 axis is critically involved in NK cell-
activating ligand regulation by IMiDs in MM cells. 
We show that CRBN knockdown can abrogate the 
capacity of lenalidomide to increase MICA and PVR/
CD155 expression, further supporting the role of this 
protein in anti-MM actions of this drug. 
Moreover, we provide evidence that the transcription 
factors IKZF1 and IKZF3 repress basal MICA and PVR/
CD155 expression in MM cells; our data indicate that 
silencing of IKZF1 or IKZF3 by shRNA interference 
(Fig. 3D-3G) or inhibition of their activity by IK6-
DN overexpression (Suppl. Fig. 8A-8D) is sufficient to 
increase MICA and PVR/CD155 expression, both at 
protein and mRNA levels.
IKZF1 and IKZF3 transcription factors are able to 
bind the same regulatory elements of their target genes, 
either as homo- or heterodimers [35, 38]. We observed 
that knockdown of IKZF1 or IKZF3 results in a similar 
increase of NK cell-activating ligand expression, thus 
indicating that both transcription factors can suppress their 
expression. 
We also identified a region of the pvr promoter 
containing an Ikaros response element and interacting 
with IKZF1 and IKZF3, supporting a direct involvement 
of these proteins in the transcriptional regulation of 
this ligand (Fig. 4C, 4D). Moreover, a site-directed 
mutagenesis revealed the involvement of two different 
proximal regions in the repression of mica promoter by 
IKZF1/3, and ChIP analysis showed that both IKZF1 and 
IKZF3 directly interact with this promoter in vivo (Fig. 
4A, 4B). Interestingly, Ikaros consensus sites overlap a 
region of mica promoter, previously identified as an heat 
shock response element (HSE), critical for the induction 
of this promoter, as well as micb promoter, by different 
stress conditions via HSF1 activation [17, 50]. Of note, 
mica and micb promoters are highly homologous, yet our 
data indicate a different regulation of these ligands in MM 
cells. Indeed, we did not observe a significant stimulatory 
effect of IMiDs or IKZF1/3 silencing on MICB expression, 
both at protein and mRNA levels, either in MM cell lines 
or primary malignant plasma cells; a possible explanation 
could be that Ikaros response elements are not conserved 
in micb promoter (Table 3). 
IMiDs can epigenetically regulate different genes in 
MM cells [36, 51, 52], and histone deacetylase (HDAC) 
or DNA methylation inhibitors can induce NKG2D ligand 
expression in different cancer cells [53-56]; moreover, a 
possible role of epigenetic mechanisms in the regulation 
of PVR/CD155 expression has been also described [57]. 
In this regard, IKZF1/3 transcription factors can promote 
gene repression or activation through their ability to 
recruit, via their C-terminus, a large number of nuclear 
co-factors, including components of both HDAC and 
ATP-dependent chromatin remodeling complexes [58-60]. 
Thus, epigenetic modifications likely can contribute to 
IKZF1/3-dependent repression of mica and pvr promoter 
activity. Further experiments will be needed to address this 
point.
In addition, our data indicate that mica promoter 
activity can be also indirectly repressed by IKZF1/3 
via IRF4 [34-36], another transcription factor emerged 
in our study as a novel negative repressor of MICA 
expression. Indeed, IRF4 silencing was sufficient, per sé, 
to significantly and specifically increase MICA expression, 
both at protein and mRNA levels (Fig. 6). 
IRF4 can positively and negatively regulate different 
genes, in part, by binding to distinct DNA-binding 
motifs and through interaction with various additional 
transcription factors [61]; its C-terminal transactivation 
domain is critical for gene activation, while the 
mechanisms responsible for gene repression are not well 
defined. 
Here, we demonstrated that the DNA binding 
activity of IRF4 is necessary for its inhibitory role on 
MICA expression (Fig. 7); in this regard, by computer 
analysis of the hMICA 5’-flank, we could identify several 
putative IRF4 binding sites. Our data tend to rule out a 
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possible regulation of IKZF1 and IKZF3 proteins by 
IRF4 (Fig. 8), and suggest that the repressive effect of this 
transcription factor on MICA expression occurs via IKZF1 
and IKZF3 independent mechanisms. Further studies will 
be needed to better clarify a direct or indirect repressive 
role of IRF4 on mica promoter.
In conclusion, we propose a model in which 
IKZF1/3 can repress the constitutive expression of MICA 
and PVR/CD155 expressed on MM cells, while IRF4 is 
able to inhibit only MICA. 
IMiDs promote the CRBN-dependent degradation 
of IKZF1/3 proteins, leading to de-repression of pvr 
promoter and to an initial de-repression of mica promoter, 
further enhanced when also IRF4 is downregulated. 
In this context, further experiments will be necessary 
to investigate the possibility that these regulatory 
mechanisms could be involved also in other cell lines (e.g. 
lymphoma, AML, MDS).
These findings provide new insights on the immuno-
mediated antitumor activities of IMiDs and further 
elucidate the molecular mechanisms that regulate NK cell-
activating ligand expression. 
MATERIALS AND METHODS
Cell lines and clinical samples
Human myeloma cell lines SKO-007(J3), ARP-
1 and OPM-2 were kindly provided by Prof. P. Trivedi 
(University of Rome, Sapienza, Italy). The human MM 
cell lines JJN-3 and KMS-27 were kindly provided by 
Prof. N. Giuliani (University of Parma, Italy). These cell 
lines were maintained at 37°C and 5% CO2 in RPMI 1640 
supplemented with 10% FCS, 2 mM L-glutamine, 100 
U/ml penicillin and 100 U/ml streptomycin (complete 
medium). The human 293T embryonic kidney cells were 
purchased from ATCC and were maintained in Dulbecco’s 
modified Eagle’s supplemented with 10% FCS. All cell 
lines were mycoplasma-free (EZ-PCR Mycoplasma Test 
Kit, Biological Industries). 
Bone marrow samples from patients with MM were 
managed at the Division of Hematology, Department of 
Cellular Biotechnologies and Hematology, University of 
Rome, Sapienza, Italy. Informed consent in accordance 
with the Declaration of Helsinki was obtained from 
all patients, and approval was obtained from the Ethics 
Committee of the Sapienza University of Rome. The bone 
marrow aspirates were processed as already described in 
[62]. In some experiments, myeloma cells were selected 
using anti-CD138 magnetic beads (Miltenyi Biotec). 
More than 95% of the purified cells expressed CD138 and 
CD38.
Reagents and antibodies
Lenalidomide was purchased from (BioVision 
Inc.), Pomalidomide and Phthalimide were purchased 
from (Sigma-Aldrich). These drugs were dissolved in 
dimethylsulphoxide (DMSO) and stored at -20°C until 
use. The final concentration of DMSO in all experiments 
was < 0.1%. 
The following monoclonal antibodies (mAbs) were 
used for immunostaining or as blocking Abs: anti-MICA 
(MAB159227), anti-MICB (MAB236511), anti-ULBP-1 
(MAB170818), anti-ULBP-2/5/6 (MAB165903), anti-
ULBP-3 (MAB166510) and anti-NKG2D (MAB149810) 
from (R&D System), anti-PVR/CD155 (SKII.4) kindly 
provided by Prof. M. Colonna (Washington University, 
St Louis, MO), anti-CD56 (C218) mAb was provided by 
Dr. A. Moretta (University of Genoa, Genoa, Italy), anti-
DNAM-1 (DX11) from (Serotec), APC Goat anti-mouse 
IgG (Poly4053), anti-CD3/APC (HIT3a), anti-CD56/
PE (HCD56), mouse IgG1/FITC, /PE or /APC isotype 
control (MOPC-21) were purchased from (BioLegend). 
Anti-CD107a/FITC (H4A3), anti-CD138-FITC (M15) 
and anti-CD38-APC (HIT2) were purchased from (BD 
Biosciences).
Flow cytometry and degranulation assay
SKO-007(J3), ARP-1, OPM-2, JJN-3 and KMS-
27 cells were cultured in 6-well tissue culture plates for 
72h at a concentration of 2 x 105 cells/ml in the presence 
of the indicated drug. The expression of the NKG2D 
and DNAM-1 ligands on MM cells was analyzed by 
immunofluorescence staining using anti-MICA, anti-
MICB or anti-PVR/CD155 unconjugated mAb, followed 
by secondary GAM-APC. In all experiments, cells were 
stained with Propidium Iodide (PI) (1 µg/ml) in order 
to assess cell viability (always higher than 90% after 
the different treatments). Nonspecific fluorescence was 
assessed by using an isotype-matched irrelevant mAb 
(R&D System) followed by the same secondary antibody. 
Fluorescence was analyzed using a FACSCalibur flow 
cytometer (BD Biosciences) and data were analyzed using 
FlowJo Flow Cytometric Data Analysis Software (Tree 
Star, Inc.).
NK cell-mediated cytotoxicity was evaluated using 
the lysosomal marker CD107a as previously described 
[17]. As source of effector cells, we used primary NK cells 
obtained from PBMCs isolated from healthy donors by 
Lymphoprep (Nycomed) gradient centrifugation and then 
co-cultured for 10 days with irradiated (30 Gy) Epstein-
Barr virus (EBV)-transformed B-cell line RPMI 8866 at 
37°C in a humidified 5% CO2 atmosphere, as previously 
described [17]. On day 10, the cell population was 
routinely more than 90% CD56+CD16+CD3-, as assessed 
by immunofluorescence and flow cytometry analysis. 
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When patient-derived plasma cells were used as targets, 
autologous CD138- bone marrow cells were cultured for 2 
days in complete medium, supplemented with 200 U/mL 
IL-2, and used as source of effector cells.
Drug-treated MM cell lines or patient-derived 
plasma cells were washed twice in complete medium 
and incubated with NK cells at effector:target (E:T) ratio 
of 2.5:1, in a U-bottom 96-well tissue culture plate in 
complete medium at 37°C and 5% CO2 for 2 h. Thereafter, 
cells were washed with PBS and incubated with anti-
CD107a/FITC (or cIgG/FITC) for 45 min at 4°C. Cells 
were then stained with anti-CD3/APC, anti-CD56/PE and 
anti-CD16/PerCP-Cy5.5 to gate the CD3-CD56+ CD16+ 
NK cell population. In some experiments, cells were pre-
treated for 20 min at room temperature with anti-NKG2D 
or anti-DNAM-1 neutralizing mAbs. Fluorescence was 
analyzed using a FACSCalibur flow cytometer (BD 
Biosciences) and data were analyzed using FlowJo Flow 
Cytometric Data Analysis Software (Tree Star).
Plasmids
For knocking down CRBN and IRF4 we used a 
pLKO.1-sh-Cereblon (TRCN0000141562) or a pLKO.1-
sh-IRF4 (TRCN0000014764) lentiviral vector and the 
control vector pLKO non-targeting shRNA (MISSION™ 
Sigma-Aldrich). For knocking down IKZF1 and IKZF3 
we used a pLKO.1-sh-IKZF1 (TRCN0000236420) or 
a IKZF3 (TRCN0000414188) GFP-lentiviral vector 
(MISSION™ Sigma-Aldrich). The retroviral vectors 
pMYs-IRES-EGFP and pMYs-IK6-IRES-EGFP, encoding 
a dominant negative isoform of Ikaros transcription 
factors, were kindly provided by Dr. Nosaka T. (Graduate 
School of Medicine, Mie University, Japan) [44]. The 
lentiviral vectors CAG-IRES-GFP encoding IKZF1 were 
kindly provided by Dr. Kaelin W.G. (Dana-Farber Cancer 
Institute, Boston, MA, USA) [34]. The lentiviral vectors 
MICA (HPRM 15126-LvPG04) and PVR/CD155 (HPRM 
13303-LvPG04) promoter reporter and NEG-LVPG04 
negative control were purchased from (GeneCopoeia 
Inc., Rockville, MD). The retroviral vectors pMX-IRF4 
(1-405) and pMX-IRF4 (403-1356), encoding truncated 
forms of human IRF4 consisting of its N-terminal DNA 
binding domain and its C-terminal association domain 
respectively, were generated by inserting the mutant 
IRF4 cDNAs obtained from the expression vector 
pcDNA3-IRF4 (1-405) and pcDNA3-IRF4 (403-1356) 
(kindly provided by Dr. Hayashi H., Graduate school of 
medical Sciences, Nagasaki University, Japan) [63], in 
the retrovirus pMX/PIE-GFP. MICA-270 bp promoter in 
pGL3-basic luciferase vector (Promega Corp., Madison, 
WI) was generated as previously described [62]. The 
mutant MICA promoter constructs (270bp-MICA-DEL1 
and 270bp-MICA- vector DEL2) were generated using 
Quick Change Site-Directed Mutagenesis Kit (Statagene) 
following the manufacturer’s instructions. Four primers 
were designed to generate two different deletions of 
the Ikaros binding site (responsive element) in the 
MICA promoter region of the pGL3-270 bp MICA. The 
sequences were the following: 
270 bp MICA prom. DEL1 sense, 
5’-CTCCCCAGGTCTCCTTTTCTCTTCCAAGCG-3’:
270 bp MICA prom. DEL1 antisense 
5’-CGCTTGGAAGAGAAAAGGAGACCTG 
GGGAG-3’; 
270 bp MICA prom. DEL2 sense 
5’-CTCCAGCCCACTGGAAGCGTGGCCCCGCC-3’; 
270 bp MICA prom. DEL2 antisense 
5’-GGCGGGGCCACGCTTCCAGTGGGCTGGAG-3’. 
All constructs were verified by DNA sequence 
analysis.
The different deletions of the human PVR/CD155 
promoter (in pGL2-basic luciferase vector, Promega 
Corp.) were kindly provided by Dr. Bernhardt G. 
(Hannover Medical School, Hannover, Germany) [64].
DNA transfections, virus production and in vitro 
transduction
293T cells were transfected with 0.5 µg of MICA-
270 bp/pGL3 basic or PVR/pGL2 basic luciferase 
reporter plus 0.125 µg of expression vector encoding 
IKZF1 using Lipofectamine Plus (Life Technologies). 
A RSV-gal expression vector was co-transfected to 
normalize DNA uptake. After 48h, cells were harvested 
and protein extracts were prepared for the luciferase and 
beta-galactosidase assays as already described in [65]. 
For MICA and PVR/CD155 lentiviral promoter vectors, 
Gaussia luciferase and secreted Alkaline Phosphatase 
activities were determined using Secrete-PairTM Dual 
Luminescence Assay Kit (GeneCopoeia Inc.) and read 
using the Glomax Multi Detection System (Promega 
Corp.) following the manufacturer’s instructions.
For retrovirus production, Phoenix cells were 
transfected with 5 μg of viral DNA using Lipofectamine 
Plus (Life Technologies). The lentiviral vectors were 
cotransfected together the packaging vectors pVSVG and 
psPAX2 into 293T cells using Lipofectamine Plus. After 
transfection, the cells were placed in fresh medium. After 
a further 48-hour culture, virus-containing supernatants 
were harvested, filtered, and used immediately for 
infections. Infections were performed on 0.5 x 106 SKO-
007(J3) cells in 2 ml complete medium with Polybrene (8 
μg/ml) (hexadimethrine bromide; Sigma-Aldrich) for 2 h. 
For GFP-expressing viruses, the infection efficiency was 
measured by FACS analysis of GFP expression at day 3 
after infection. In some experiments, SKO-007(J3) cells 
infected by retrovirus pMYs-IK6-IRES-EGFP or pMYs-
IRES-EGFP were sorted based on GFP expression using a 
FACSAria (BD Biosciences) equipped with a 488nm laser 
and FACSDiva software (BD Biosciences version 6.1.3). 
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Briefly, cells first gated based on forward and side scatter 
area (FSC-A and SSC-A) plot were then detected in the 
green fluorescence channel for GFP expression. 
RNA isolation, quantitative Real-Time polymerase 
chain reaction (qRT-PCR), and chromatin 
immunoprecipitation (ChIP) assay
Total RNA was extracted using TRIZOLTM (Life 
Technologies), according to manufacturer’s instructions. 
The concentration and quality of the extracted total RNA 
was determined by measuring light absorbance at 260 nm 
(A260) and the ratio of A260/A280. Reverse transcription was 
carried out in a 25 µl reaction volume with 2 µg of total 
RNA according to the manufacturer’s protocol for M-MLV 
reverse transcriptase (Promega). Real-Time qRT-PCR 
was performed using TaqMan assays and the ABI Prism 
7900 Sequence Detection system (Applied Biosystems). 
cDNAs were amplified in triplicate with primers for 
MICA (Hs00792195_m1), MICB (Hs00792952_m1), 
PVR/CD155 (Hs00197846_m1), CRBN (Hs00372271_
m1) and GAPDH (Hs03929097_g1) conjugated with 
fluorochrome FAM (Applied Biosystems). The level of 
expression was measured using Ct (threshold cycle). The 
Ct was obtained by subtracting the Ct value of the gene of 
interest from the housekeeping gene (GAPDH) Ct value. 
In the present study, we used Ct of the untreated sample as 
the calibrator. The fold change was calculated according to 
the formula 2-∆∆Ct, where ∆∆Ct was the difference between 
Ct of the sample and the Ct of the calibrator (according to 
the formula, the value of the calibrator in each run is 1). 
The analysis was performed using the SDS version 2.4 
software (Applied Biosystems).
ChIP assays were done using Magna Chip 
kit protocol (EMD Millipore, Bedford, MA); after 
sonication, chromatin samples were immunoprecipitated 
overnight with 10 µg of a polyclonal rabbit anti-Ikaros 
(H-100), polyclonal goat anti-Aiolos antibody (L-15) 
(Santa Cruz Biotechnology) or isotype control and 20 
µl of fully suspended protein A/G magnetic beads. The 
immunocomplexes/beads were washed sequentially 
with low-salt buffer, high-salt buffer, LiCl wash buffer 
and TE buffer, as detailed in the Upstate Biotechnology 
protocol. Precipitated were extracted with an elution 
buffer (1% SDS/0.1 M NaHCO3) and digested with 
proteinase K for 2 h at 62°C. DNA was purified using spin 
columns and eluted in 50 µl of DEPC-water. Fractions 
of pre-cleared chromatin (1%) were processed similar to 
immunoprecipitated chromatin, for input DNA controls. 
The purified DNA was quantified in triplicate using 
Real-Time PCR and the Power-SYBR green mix with 
ROX (Applied Biosystems). Primer sequences were as 
follows: 
MICA promoter forward: 
5’-AGGTCTCCAGCCCACTGGAATTTTCTC-3’; 
MICA promoter reverse: 
5’-CGCCACCCTCTCAGCGGCTCAAGC-3’; 
PVR promoter forward: 
5’-CAGGATCTGTCCCATCACGAGTTGG-3’; 
PVR promoter reverse: 
5’-GCTCCGTCGGTGCCCACTAGA-3’. 
PCRs were validated by the presence of a single 
peak in the melt curve analysis, and amplification of 
a single specific product was further confirmed by 
electrophoresis on agarose gel. Results are expressed as 
relative enrichment as compared to the input. Negative 
control (no antibody) values were subtracted from the 
corresponding samples. Absolute quantifications were 
obtained by serial dilutions of the input DNA samples. 
The analysis was performed using the SDS version 2.4 
software (Applied Biosystems).
Western-blot analysis
For Western-Blot analysis, SKO-007(J3) cells were 
pelleted, washed once with cold phosphate-buffered 
saline, resuspended in lysis buffer [1% Nonidet P-40 (v/v), 
10% glycerol, 0.1% SDS, 0.5% Sodium Deoxycholate, 1 
mM phenyl-methyl-sulfonyl fluoride (PMSF), 10 mM 
NaF, 1 mM Na3VO4, complete protease inhibitor mixture 
(Roche) in PBS] and subsequently incubated 30 min on 
ice. The lysate was centrifuged at 14000g for 15 min 
at 4°C and the supernatant was collected as whole cell 
extract. Protein concentration was determined by the BCA 
method (Pierce). Thirty to 50 µg of cell extract was run 
on 12.5% denaturing SDS-polyacrylamide gels. Proteins 
were then electroblotted onto nitrocellulose membranes 
(Schleicher&Schuell), stained with Ponceau to verify that 
similar amounts of proteins had been loaded in each lane, 
and blocked in 3% milk in TBST buffer. Immunoreactive 
bands were visualized on the nitrocellulose membranes, 
using horseradish-peroxidase-coupled goat anti-rabbit or 
goat anti-mouse immunoglobulins and the ECL detection 
system (GE Healthcare Amersham), following the 
manufacturer’s instructions. Antibodies against β-actin, 
IRF4 (H-140), Ikaros (H-100) and Aiolos (L-15) were 
purchased from Santa Cruz Biotechnology. Antibody 
against Blimp-1 was purchased from Cell Signaling.
Statistics
Error bars represent SD. Data were evaluated by 
paired Student t test and a level of P< 0.05 was considered 
statistically significant. 
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